

**Fellow Publications/Presentations
January through December 2019**

Publications

1. **Chakraborty R**, Sidana S, Shah G, et. al. Patient-Reported Outcomes With Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities. *Biol Blood Marrow Transplant.* 25 (5), e155-e162. May 2019. PMID: 30500439
2. **Chakraborty R**, Majhail N, Anwer F. Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma: What Are the Unanswered Questions? *JAMA Oncol.* June 2019 [Online ahead of print]. PMID: 31246229
3. **Chakraborty R**, Liu H, Rybicki L, et. al. Progression With Clinical Features Is Associated With Worse Subsequent Survival in Multiple Myeloma. *Am J Hematol.* 94 (4), 439-445. Apr 2019. PMID: 30663805
4. **Chakraborty R**, Rybicki L, Tomer J, et. al. Patient-reported Outcomes in Systemic AL Amyloidosis With Functional Assessment of Cancer Therapy-General (FACT-G) and Patient-Reported Outcomes Measurement Information System-Global Health (PROMIS-GH) in a Real-World Population. *Leuk Lymphoma*, 60 (14), 3544-3551. Dec 2019. PMID: 31272258
5. **Fallah J**, Rini B. HIF Inhibitors: Status of Current Clinical Development. *Curr Oncol Rep.* 21 (1), 6. Jan 22, 2019. PMID: 30671662
6. **Fallah J**, Ahluwalia MS. The role of immunotherapy in the management of patients with renal cell carcinoma and brain metastases. *Ann Transl Med.* 2019 Dec;7(Suppl 8):S313.doi: 10.21037/atm.201910.31
7. **Fallah J**, Olszewski A, et. al. Diagnostic and Therapeutic Splenectomy for Splenic Lymphomas: Analysis of the National Cancer Data Base. *Hematology.* 24 (1), 378-386. Dec. 2019. PMID: 30885066
8. **Hu R**, Winter A, Hill B. The Emerging Role of Minimal Residual Disease Testing in Diffuse Large B-Cell Lymphoma. *Curr Oncol Rep*, 21 (5), 44. Apr 2019. PMID: 30941515
9. **Kishtagari A**, Jha B, Maciejewski J. TET2 Mutations and Clonal Dynamics. *Oncotarget.* 10 (21), 2010-2011. Mar 2019. PMID: 31007843
10. Durrani J, Awada H, **Kishtagari A**, et. Large Granular Lymphocytic Leukemia Coexists With Myeloid Clones and Myelodysplastic Syndrome. *Leukemia.* Oct 2019. PMID: 31624375
11. Saygin C, **Kishtagari A**, Cassaday R. Therapy-related Acute Lymphoblastic Leukemia Is a Distinct Entity With Adverse Genetic Features and Clinical Outcomes. *Blood Adv.* 3 (24), 4228-4237. Dec 2019. PMID: 31869410
12. Awada H, Mahfouz RZ, **Kishtagari A**, et. al. Extended experience with non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies. *Br J Haematol.* 2020 Mar;188(6):924-929. doi: 10.1111/bjh.16281. Epub 2019 Nov 17. PMID: 31736067

13. **Khouri J**, Samaras C, Valent J, et. al. Monoclonal Gammopathy of Undetermined Significance: A Primary Care Guide. *Cleve Clin J Med*. 86 (1), 39-46. Jan 2019. PMID: 30624183
14. **Khouri J**, Kin A, Thapa B, et. al. Daratumumab Proves Safe and Highly Effective in AL Amyloidosis. *Br J Haematol*. 185 (2), 342-344. Apr 2019. PMID: 29938774
15. **Khouri J**, Reu F, Majhail N, et. al. Low-Dose Lenalidomide After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation With Bortezomib as Graft-Versus-Host Disease Prophylaxis in High-Risk Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. e374-e376. PMID: 31053548
16. Chakraborty R, Liu HD, Rybicki L, Tomer J, **Khouri J**, et. al. Progression with clinical features is associated with worse subsequent survival in multiple myeloma. *Am J Hematol*. 2019 Apr;94(4):439-445. doi: 10.1002/ajh.25415. Epub 2019 Feb 6. PMID: 30663805.
17. **Khouri J**, Rybicki L, Majhail NS, Kalaycio M, Pohlman B, Hill B, Jagadeesh D, Dean R, Hamilton B, Sobecks R, Koo A, Liu H. Body mass index does not impact hematopoietic progenitor cell mobilization for autologous hematopoietic cell transplantation. *J Clin Apher*. 2019 Dec;34(6):638-645. doi: 10.1002/jca.21739. Epub 2019 Aug 5. PMID: 31381194.
18. Durer C, Durer S, **Lee S**. Treatment of Relapsed Multiple Myeloma: Evidence-based Recommendations. *Blood Rev*. 39, 100616. Jan 2020. PMID: 31500848
19. Barot SV, **Lee SS**, Patel BJ, et. al. Ibrutinib is Effective in Refractory Type II Cryoglobulinemia. *Clin Lymphoma Myeloma Leuk*. 2019 Dec;19(12):e629-e632. doi: 10.1016/j.clml.2019.07.442. Epub 2019 Sep 3. PMID: 31585822
20. **Madanat Y**, Kalaycio M, Nazha A. Advances in Acute Myeloid Leukemia Genomics, Where Do We Stand in 2018? *Acta Med Acad*. 48 (1), 35-44. Apr 2019. PMID: 31264431
21. **Madanat Y**, Gerds A. Can Allogeneic Hematopoietic Cell Transplant Cure Therapy-Related Acute Leukemia? *Best Pract Res Clin Haematol*. 32 (1), 104-113. Mar 2019. PMID: 30927969
22. **Madanat YF**, Sekeres MA. Wilms tumor 1 expression: addressing the 'elephant' in MDS. *Leuk Lymphoma*. 2019 Mar;60(3):566-567. doi: 10.1080/10428194.2018.1516882. Epub 2019 Feb 4. PMID: 30714447.
23. **Nizam A**, Aragon-Ching JB. Frontline immunotherapy treatment with nivolumab and ipilimumab in metastatic renal cell cancer: a new standard of care. *Cancer Biol Ther*. 2019;20(1):6-7. doi: 10.1080/15384047.2018.1507260. Epub 2018 Oct 17. PMID: 30332546
24. Aragon-Ching JB, **Nizam A**, Henson DE. Carcinomas of the Renal Pelvis, Ureters, and Urinary Bladder Share a Carcinogenic Field as Revealed in Epidemiological Analysis of Tumor Registry Data. *Clin Genitourin Cancer*. 2019 Dec;17(6):436-442. doi: 10.1016/j.clgc.2019.07.011. Epub 2019 Jul 19. PMID: 31445851

25. **Nizam A**, Aragon-Ching JB. Frontline immunotherapy treatment with nivolumab and ipilimumab in metastatic renal cell cancer: a new standard of care. *Cancer Biol Ther*. 2019;20(1):6-7. PMID: 30332546.
26. Dousa KM, De la Hoz A, Church E, **Onger T**, et. al. Progressive and disseminated histoplasma infection and hemophagocytic lymphohistiocytosis in an immunocompetent adult. *Clin Case Rep*. 2019 Mar 27;7(5):913-916. doi: 10.1002/ccr3.2079. PMID: 31110713; PMCID: PMC6509665.
27. **Patil P**, Shepherd F, Johnson D, et. al. A Career in Lung Cancer: Pushing Beyond Chemotherapy. *Am Soc Clin Oncol Educ Book*. 39, 583-589. Jan 2019. PMID: 31099660
28. **Patil P**, Hobbs B, Pennell N. The Promise and Challenges of Deep Learning Models for Automated Histopathologic Classification and Mutation Prediction in Lung Cancer. *J Thorac Dis*. 11 (2), 369-372. Feb 2019. PMID: 30962976
29. Khorrami M, Prasanna P, Gupta A, **Patil P**, et. al. Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung Cancer. *Cancer Immunol Res*. 2020 Jan;8(1):108-119. doi: 10.1158/2326-6066.CIR-19-0476. Epub 2019 Nov 12. PMID: 31719058; PMCID: PMC7718609.
30. **Patil PD**, Shapiro M, Hashemi Sadraei N, Pennell NA. An Open-Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non-Small Cell Lung Cancer. *Oncologist*. 2019 Apr;24(4):457-e126. doi: 10.1634/theoncologist.2018-0857. Epub 2019 Jan 2. PMID: 30602615; PMCID: PMC6459252.
31. Khorrami M, Jain P, Bera K, Alilou M, Thawani R, **Patil P**, et. al. Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features. *Lung Cancer*. 2019 Sep;135:1-9. doi: 10.1016/j.lungcan.2019.06.020. Epub 2019 Jul 5. Erratum in: *Lung Cancer*. 2019 Oct;136:156. PMID: 31446979; PMCID: PMC6711393.
32. Khorrami M, Khunger M, Zagouras A, **Patil P**, Combination of Peri- and Intratumoral Radiomic Features on Baseline CT Scans Predicts Response to Chemotherapy in Lung Adenocarcinoma. *Radiol Artif Intell*. 2019 Mar 20;1(2):e180012. doi: 10.1148/ryai.2019180012. PMID: 32076657; PMCID: PMC6515986.
33. **Patil PD**, Fernandez AP, Velcheti V, et. al. Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash. *Oncologist*. 2019 Jan;24(1):4-8. doi: 10.1634/theoncologist.2018-0434. Epub 2018 Oct 24. PMID: 30355774; PMCID: PMC6324641.
34. Khorrami M, Jain P, Bera K, Alilou M, Thawani R, **Patil P**, et. al. Corrigendum to "Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features" [*Lung Cancer* 135 (September) (2019) 1-9]. *Lung Cancer*. 2019 Oct;136:156. doi: 10.1016/j.lungcan.2019.08.012. Epub 2019 Aug 21. Erratum for: *Lung Cancer*. 2019 Sep;135:1-9. PMID: 31564290.

35. Kunapareddy G, Switzer B, Jain P, Conces M, Chen YW, Patel B, Patel S, **Pinnamaneni P**, Pohlman B, Angelini DE, McCrae KR, Khorana AA. Implementation of an electronic medical record tool for early detection of deep vein thrombosis in the ambulatory oncology setting. *Res Pract Thromb Haemost*. 2019 Jan 28;3(2):226-233. doi: 10.1002/rth2.12176. PMID: 31011706; PMCID: PMC6462749.
36. **Sheng I**, Rini B. Immunotherapy for Renal Cell Carcinoma. *Expert Opin Biol Ther*. 19 (9), 897-905. Sep 2019. PMID: 31173514
37. **Sheng I**, Kruse K, Leininger K, et. al. Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC). *Case Rep Oncol Med*. 2019, 6246209 eCollection. Jun 2019. PMID: 31281697
38. **Sussman TA**, Kruse ML, Thacker HL, Abraham J. Managing Genitourinary Syndrome of Menopause in Breast Cancer Survivors Receiving Endocrine Therapy. *J Oncol Pract*. 2019 Jul;15(7):363-370. doi: 10.1200/JOP.18.00710. PMID: 31291563.
39. **Sussman TA**, Abazeed ME, McCrae KR, Khorana AA. RNA expression and risk of venous thromboembolism in lung cancer. *Res Pract Thromb Haemost*. 2019 Dec 27;4(1):117-123. doi: 10.1002/rth2.12284. PMID: 31989093; PMCID: PMC6971308.
40. Hill BT, Nastoupil L, **Winter AM**, Becnel MR, et. al. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. *Br J Haematol*. 2019 Feb;184(4):524-535. doi: 10.1111/bjh.15720. Epub 2018 Dec 21. PMID: 30575016; PMCID: PMC6486816.
41. Hu R, **Winter A**, Hill BT. The Emerging Role of Minimal Residual Disease Testing in Diffuse Large B-Cell Lymphoma. *Curr Oncol Rep*. 2019 Apr 2;21(5):44. doi: 10.1007/s11912-019-0792-4. PMID: 30941515.
42. Landsburg DJ, Hughes ME, Koike A, Bond D, Maddocks KJ, Guo L, **Winter AM**, et. al. Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy. *Blood Adv*. 2019 Jan 22;3(2):132-135. doi: 10.1182/bloodadvances.2018026401. PMID: 30651281; PMCID: PMC6341198.

Poster Presentations/Abstracts

1. **Chakraborty R**, et. al. Conditional survival in patients with Multiple Myeloma undergoing upfront Autologous Stem Cell Transplant. *Transplant & Cellular Therapy Meetings of ASBMT & CIBMTR*. February 2019. (Poster)
2. **Chakraborty R**, et. al. Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapse Multiple Myeloma. *ASH Annual Meeting*. December 2019. (Poster)
3. **Desouza S**. Acquired Alpha-2 Anti-Plasmin Deficiency misdiagnosed as a FXIII deficiency. *Pre-ASH 2019 HTRS Trainee Workshop*. December 2019. (Oral)
4. **Fallah J**, et. al. Correlation of myeloid-derived suppressor cells (MDSC) with pathologic complete response (pCR), recurrence free survival (RFS), and overall survival (OS) in

patients with urothelial carcinoma (UC) undergoing cystectomy. Genitourinary Cancer Symposium. Sanfrancisco, CA. February 2019 (Poster)

5. **Fallah J**, et. al. Neoadjuvant durvalumab +/- tremelimumab affects the expression of immune checkpoint (IC) molecules on myeloid derived suppressor cells (MDSC) in patients (pts) with locally advanced renal cell carcinoma (RCC). Genitourinary Cancer Symposium. Sanfrancisco, CA. February 2019 (Poster)
6. **Fallah J**, et. al. Circulating cell free DNA (cfDNA) levels and fragmentation pattern can distinguish nonmuscle invasive (NMI) from muscle-invasive (MI) and metastatic (met) bladder cancer (BC). ASCO Annual Meeting. Chicago, IL. June 2019. (Poster)
7. **Fallah J**, et. al. Association of cell-free DNA (cfDNA) levels with myloid-derived suppressor cells (MDSC) levels in blood of patients (pts) with muscle invasive (MI) and metastatic (met) bladder cancer (BC). ASCO Annual Meeting. Chicago, IL. June 2019. (Poster)
8. **Fallah J**, et. al. Safety and efficacy of bevacizumab plus TTFields in patients with recurrent glioblastoma (GBM): data from a phase II clinical trial. Society for Neuro-Oncology Annual Scientific Meeting. Phoenix, AZ. November 2019.
9. **Hu R**, et. al. Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis. Orlando, FL. ASH Annual Meeting. December 2019. (Poster)
10. **Kishtagari A**, et. al. TET2 Loss Accelerates Leukemogenesis By Disrupting Mismatch Repair Proteins. ASH Annual Meeting. December 2019 (Poster)
11. **Kishtagari A**, et. al. Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity. ASH Annual Meeting. December 2019 (Poster)
12. **Lee S**, Rosko N, Patel B, et. al. Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Primary Refractory AL Amyloidosis. 6th Annual Global Summit Hematologic Emergencies. British Columbia, CA. March 2019. (Poster)
13. **Lee S**, Rosko N, Samaras C, et. al. Improving time to initiation of bone modifying agents in patients with newly diagnosed multiple myeloma. ASCO Annual Meeting. Chicago, IL. May 2019. (Poster)
14. **Lee S**, Switzer B, Khan M, Pinnamaneni P, et. al. A. Implementing individualized care plans in high-risk oncology patients: A team-based model to increase hospice utilization. American Society of Clinical Oncology Quality Care Symposium; San Diego, CA 2019. (Poster)
15. **Nizam A**, Henson DE, Aragon-Ching JB. Carcinomas of the renal pelvis, ureters, and urinary bladder arise by similar carcinogenic pathways: a pathoepidemiological analysis. Poster presentation at American Society of Clinical Oncology Genitourinary Cancers Symposium; February 15, 2019; San Francisco, CA (Poster)

1. **Madanat Y**, Mukherjee S, Patel B, et. al. Intra-risk group heterogeneity in Myelodysplastic Syndromes. Acute Leukemia Forum. Newport Beach, CA. April 2019. (**Oral**)
2. **Madanat Y**, Sekeres M, Mukherjee S, et. al. GenomicBiomarkers Can Predict Response/Resistance to Lenalidomide in Non-Del (5q) Myelodysplastic Syndromes. Acute Leukemia Forum. Newport Beach, CA. April 2019. (**Oral**)
3. **Patil, P**, Khorrami K, Zagouras A, et. al. Novel CT Based Radiomic Features Are Prognostic and Predictive of Benefit of Chemoimmunotherapy in Advanced Non-Squamous NSCLC. 2019 World Conference on Lung Cancer. Barcelona, Spain. September, 2019. (**Oral**)
4. **Patil, P**, Jia X, Hobbs B, et. al. The Impact of Early Steroids on Clinical Outcomes in Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors – A Cancerliq Cohort. 2019 World Conference on Lung Cancer. Barcelona, Spain. September, 2019. (Poster)
5. **Patil, P**. Predictive and prognostic value of radiomic biomarkers in patients with advanced non-small cell lung cancer treated with chemoimmunotherapy. Presented at Prime Oncology Forum for Young Investigators in Lung Cancer; Atlanta, GA. 05/2019. (**Oral**)
6. **Sadaps M**, et. al. Tumor size and the risk for lymph node metastases in T1 esophageal adenocarcinoma. Presented at Gastrointestinal Cancers Symposium; San Francisco, CA. 01/24/2019 (Poster)
7. **Sadaps M**, et. al., A multi-institutional study assessing prevalence of deleterious germline mutations in pancreatic cancer. 2019 Gastrointestinal Cancers Symposium. San Francisco, CA. January 2019 (Poster)
8. **Sadaps M**, et. al. Precision Oncology in Pancreatobiliary Cancers: A Longitudinal Study. Presented at UEG Annual Meeting; Barcelona, Spain. 10/11/2019. (**Oral**)
9. **Sadaps, M**, et. al. Tumor Size Increases the Risk for Lymph Node Metastases in T1b Esophageal Adenocarcinoma. United European Gastroenterology Week (UEG) 2019. UEG Annual Meeting. Barcelona, Spain. October 2019. (Poster)
10. **Sheng I**, et. al. Blood myeloid derived suppressor cells (MDSC) in metastatic urothelial carcinoma (mUC) are correlated with neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS). Genitourinary Cancer Symposium. Sanfrancisco, CA. February 2019 (Poster)
11. **Sheng I**, et. al. Implications of the United States Preventative Services Task Force (USPSTF) recommendations on prostate cancer (PCa) stage migration. ASCO Annual Meeting. Chicago, IL. June 2019 (Poster)
12. **Sussman T**, et. al. Clinical Outcomes in Melanoma Patients with Family or Personal History of Cancer. Society for Melanoma Research 16th International Congress. Salt Lake City, UT. November 2019 (Poster)
13. **Sussman T**, et. al. Incidence and Outcome of Venous Thromboembolism in Melanoma Patients on Immunotherapy Stratified by Presence of Brain Metastases. Society for

Melanoma Research 16th International Congress.Salt Lake City, UT. November 2019
(Poster)